Diseases /
Endometrial Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant tumor arising from the epithelium that lines the cavity of the uterine body. The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases. Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma. Uterine bleeding is an initial clinical sign. The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation. [1]
Endometrial carcinomas most frequently harbor alterations in PTEN, PIK3CA, TP53, ARID1A, and PIK3R1 [2].
PTEN Mutation, PIK3CA Mutation, TP53 Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in endometrial carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for endometrial carcinoma, 3 are FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting [3].
Dostarlimab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Indicated for the treatment of mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. |
Lenvatinib + Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: FDA granted accelerated approval to the combination of pembrolizumab (KEYTRUDA, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. |
Clinical Trials
There are 126 clinical trials for endometrial carcinoma, of which 110 are open and 16 are completed or closed. Of the trials that contain endometrial carcinoma as an inclusion criterion, 2 are early phase 1 (2 open), 42 are phase 1 (35 open), 28 are phase 1/phase 2 (22 open), 43 are phase 2 (40 open), 1 is phase 2/phase 3 (1 open), and 10 are phase 3 (10 open).
Deficient, MLH1, and MSH2 are the most frequent gene inclusion criteria for endometrial carcinoma clinical trials [3].
Pembrolizumab, paclitaxel, and carboplatin are the most common interventions in endometrial carcinoma clinical trials.
Significant Genes in Endometrial Carcinoma
AKT1 +
AKT1 is altered in 4.94% of endometrial carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
AKT2 +
AKT2 is altered in 3.12% of endometrial carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
AKT3 +
AKT3 is altered in 3.85% of endometrial carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ALK +
ALK is altered in 6.01% of endometrial carcinoma patients [2].
ALK is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ARAF +
ARAF is altered in 5.05% of endometrial carcinoma patients [2].
ARAF is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is altered in 41.6% of endometrial carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
ATM +
ATM is altered in 11.39% of endometrial carcinoma patients [2].
ATM is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATM status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ATR +
ATR is altered in 6.78% of endometrial carcinoma patients [2].
ATR is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATR status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ATRX +
ATRX is altered in 9.25% of endometrial carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
BAP1 +
BAP1 is altered in 2.53% of endometrial carcinoma patients [2].
BAP1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 3.21% of endometrial carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BARD1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
BRAF +
BRAF is altered in 5.0% of endometrial carcinoma patients [2].
BRAF is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BRCA1 +
BRCA1 is altered in 5.12% of endometrial carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 9 clinical trials for endometrial carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA1 status and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [3].
BRCA2 +
BRCA2 is altered in 9.16% of endometrial carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 9 clinical trials for endometrial carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA2 status and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [3].
BRIP1 +
BRIP1 is altered in 4.49% of endometrial carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRIP1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.37% of endometrial carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain C11orf30 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
CCNE1 +
CCNE1 is altered in 4.97% of endometrial carcinoma patients [2].
CCNE1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 5.58% of endometrial carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDK12 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is altered in 1.99% of endometrial carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
CHEK2 +
CHEK2 is altered in 3.52% of endometrial carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
CRKL +
CRKL is altered in 1.46% of endometrial carcinoma patients [2].
CRKL is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
EGFR +
EGFR is altered in 4.71% of endometrial carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ERBB2 +
ERBB2 is altered in 8.93% of endometrial carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 10 clinical trials for endometrial carcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERBB2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
ERBB3 +
ERBB3 is altered in 8.48% of endometrial carcinoma patients [2].
ERBB3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 3.82% of endometrial carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC3 +
ERCC3 is altered in 3.91% of endometrial carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC4 +
ERCC4 is altered in 3.91% of endometrial carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 5.58% of endometrial carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC5 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC6 +
ERCC6 is altered in 1.93% of endometrial carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
FANCA +
FANCA is altered in 5.15% of endometrial carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCA status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCB +
FANCB is altered in 4.47% of endometrial carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCB status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCC +
FANCC is altered in 2.25% of endometrial carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCC status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is altered in 4.89% of endometrial carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCD2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCE +
FANCE is altered in 2.84% of endometrial carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCE status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCF +
FANCF is altered in 1.8% of endometrial carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCF status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCG +
FANCG is altered in 2.87% of endometrial carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCG status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCI +
FANCI is altered in 4.21% of endometrial carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCI status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCL +
FANCL is altered in 2.7% of endometrial carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCL status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCM +
FANCM is altered in 8.94% of endometrial carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCM status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF10 +
FGF10 is altered in 2.58% of endometrial carcinoma patients [2].
FGF10 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF12 +
FGF12 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF14 +
FGF14 is altered in 0.22% of endometrial carcinoma patients [2].
FGF14 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF16 +
FGF16 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF18 +
FGF18 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF19 +
FGF19 is altered in 2.01% of endometrial carcinoma patients [2].
FGF19 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF21 +
FGF21 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF23 +
FGF23 is altered in 1.95% of endometrial carcinoma patients [2].
FGF23 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF3 +
FGF3 is altered in 2.43% of endometrial carcinoma patients [2].
FGF3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF4 +
FGF4 is altered in 2.18% of endometrial carcinoma patients [2].
FGF4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF5 +
FGF5 is altered in 5.88% of endometrial carcinoma patients [2].
FGF5 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF6 +
FGF6 is altered in 1.94% of endometrial carcinoma patients [2].
FGF6 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF7 +
FGF7 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF8 +
FGF8 is altered in 0.09% of endometrial carcinoma patients [2].
FGF8 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FGFR1 +
FGFR1 is altered in 3.61% of endometrial carcinoma patients [2].
FGFR1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FGFR2 +
FGFR2 is altered in 9.95% of endometrial carcinoma patients [2].
FGFR2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FGFR3 +
FGFR3 is altered in 4.23% of endometrial carcinoma patients [2].
FGFR3 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FGFR4 +
FGFR4 is altered in 3.5% of endometrial carcinoma patients [2].
FGFR4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
HDAC1 +
HDAC1 is altered in 3.57% of endometrial carcinoma patients [2].
HDAC1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
HRAS +
HRAS is altered in 1.48% of endometrial carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
KRAS +
KRAS is altered in 19.6% of endometrial carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 5 clinical trials for endometrial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [3].
MAP2K1 +
MAP2K1 is altered in 1.43% of endometrial carcinoma patients [2].
MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is altered in 1.97% of endometrial carcinoma patients [2].
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP2K4 +
MAP2K4 is altered in 2.76% of endometrial carcinoma patients [2].
MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP3K1 +
MAP3K1 is altered in 8.15% of endometrial carcinoma patients [2].
MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAPK1 +
MAPK1 is altered in 1.88% of endometrial carcinoma patients [2].
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCL1 +
MCL1 is altered in 2.4% of endometrial carcinoma patients [2].
MCL1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MCPH1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is altered in 1.67% of endometrial carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MDM4 +
MDM4 is altered in 1.98% of endometrial carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MET +
MET is altered in 4.83% of endometrial carcinoma patients [2].
MET is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
MLF1 +
MLF1 is altered in 0.27% of endometrial carcinoma patients [2].
MLF1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MLH1 +
MLH1 is altered in 4.2% of endometrial carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLH1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MLH3 +
MLH3 is altered in 6.46% of endometrial carcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MRE11A +
MRE11A is altered in 4.11% of endometrial carcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MRE11A status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is altered in 5.87% of endometrial carcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MSH3 +
MSH3 is altered in 7.32% of endometrial carcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MSH6 +
MSH6 is altered in 8.02% of endometrial carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
MTOR +
MTOR is altered in 9.43% of endometrial carcinoma patients [2].
MTOR is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
MUTYH +
MUTYH is altered in 2.88% of endometrial carcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MYC +
MYC is altered in 5.93% of endometrial carcinoma patients [2].
MYC is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
NBN +
NBN is altered in 4.19% of endometrial carcinoma patients [2].
NBN is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
NF1 +
NF1 is altered in 10.67% of endometrial carcinoma patients [2].
NF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
NPM1 +
NPM1 is altered in 1.16% of endometrial carcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NRAS +
NRAS is altered in 3.04% of endometrial carcinoma patients [2].
NRAS is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PALB2 +
PALB2 is altered in 4.49% of endometrial carcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
PARP1 +
PARP1 is altered in 3.4% of endometrial carcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 4.53% of endometrial carcinoma patients [2].
PDGFRA is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3CA +
PIK3CA is altered in 45.81% of endometrial carcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 5 clinical trials for endometrial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PIK3CA status and endometrial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].
PIK3CG +
PIK3CG is altered in 5.64% of endometrial carcinoma patients [2].
PIK3CG is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3R1 +
PIK3R1 is altered in 26.49% of endometrial carcinoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
PIK3R2 +
PIK3R2 is altered in 4.57% of endometrial carcinoma patients [2].
PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
PMS1 +
PMS1 is altered in 2.87% of endometrial carcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PMS2 +
PMS2 is altered in 3.51% of endometrial carcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PMS2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
POLE +
POLE is altered in 9.25% of endometrial carcinoma patients [2].
POLE is an inclusion eligibility criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain POLE status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
PPP2R1A +
PPP2R1A is altered in 16.26% of endometrial carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R1A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R2A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
PTEN +
PTEN is altered in 48.03% of endometrial carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 8 clinical trials for endometrial carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PTEN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
RAD50 +
RAD50 is altered in 3.74% of endometrial carcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD50 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD51 +
RAD51 is altered in 0.66% of endometrial carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD51B +
RAD51B is altered in 1.09% of endometrial carcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51B status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is altered in 1.72% of endometrial carcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51C status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD51D +
RAD51D is altered in 1.38% of endometrial carcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51D status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAD54L +
RAD54L is altered in 3.17% of endometrial carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD54L status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is altered in 3.07% of endometrial carcinoma patients [2].
RAF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
RET +
RET is altered in 4.49% of endometrial carcinoma patients [2].
RET is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
RICTOR +
RICTOR is altered in 5.23% of endometrial carcinoma patients [2].
RICTOR is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ROS1 +
ROS1 is altered in 7.53% of endometrial carcinoma patients [2].
ROS1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RPTOR +
RPTOR is altered in 4.69% of endometrial carcinoma patients [2].
RPTOR is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
SLX4 +
SLX4 is altered in 7.55% of endometrial carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain SLX4 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 1.85% of endometrial carcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
SRC +
SRC is altered in 2.03% of endometrial carcinoma patients [2].
SRC is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 6.33% of endometrial carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STAG2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
STK11 +
STK11 is altered in 2.83% of endometrial carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain STK11 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
TP53 +
TP53 is altered in 40.3% of endometrial carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and endometrial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].
TSC1 +
TSC1 is altered in 5.39% of endometrial carcinoma patients [2].
TSC1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TSC2 +
TSC2 is altered in 7.26% of endometrial carcinoma patients [2].
TSC2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
XRCC1 +
XRCC1 is altered in 4.07% of endometrial carcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain XRCC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
